Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Biocept Inc (BIOC)

Biocept Inc (BIOC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 60,135
  • Shares Outstanding, K 13,393
  • Annual Sales, $ 5,530 K
  • Annual Income, $ -25,140 K
  • 60-Month Beta 0.64
  • Price/Sales 10.61
  • Price/Cash Flow N/A
  • Price/Book 2.20

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.48
  • Number of Estimates 1
  • High Estimate -0.48
  • Low Estimate -0.48
  • Prior Year -2.50
  • Growth Rate Est. (year over year) +80.80%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.46 +29.77%
on 09/11/20
9.15 -50.93%
on 08/19/20
-4.63 (-50.79%)
since 08/18/20
3-Month
3.46 +29.77%
on 09/11/20
13.00 -65.46%
on 08/06/20
-5.01 (-52.74%)
since 06/18/20
52-Week
2.11 +112.59%
on 03/17/20
13.00 -65.46%
on 08/06/20
-4.26 (-48.70%)
since 09/18/19

Most Recent Stories

More News
Biocept Provides COVID-19 Testing Update with More than 35,000 Specimens Received

, /PRNewswire/ -- . (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve patient outcomes, announces...

BIOC : 4.49 (+2.51%)
Aegea Biotechnologies, Inc. Advances to Semi-Finals of the $5M XPRIZE Rapid COVID Testing Competition

, /PRNewswire/ -- Aegea Biotechnologies, Inc. (, "Aegea"), a biotechnology company focusing on the development and commercialization of next generation nucleic acid and clinical diagnostic technologies,...

BIOC : 4.49 (+2.51%)
Biocept to Present at the H.C. Wainwright Global Investment Virtual Conference on September 14

, /PRNewswire/ -- . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostics designed to provide physicians with clinically actionable information to improve the patient outcomes, announces...

BIOC : 4.49 (+2.51%)
Biocept Executes In-Network Provider Agreement with Health Net Federal Services Extending Coverage for its Liquid Biopsy Oncology Platform to the TRICARE West Region Network

, /PRNewswire/ -- . (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve patient outcomes, announces...

BIOC : 4.49 (+2.51%)
Biocept Announces One-for-Ten Reverse Stock Split

, /PRNewswire/ -- . (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve patient outcomes, announces...

BIOC : 4.49 (+2.51%)
LD Micro - 360 Companies Set to Present this Week

LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.

ACRX : 1.5700 (+14.60%)
ACER : 2.59 (+1.97%)
ACU : 23.36 (+4.05%)
AT.VN : 1.610 (-0.62%)
AEY : 2.04 (-1.45%)
ADIL : 1.3200 (+1.54%)
ADTX : 1.9400 (-2.02%)
ADXS : 0.4450 (+2.63%)
AEHR : 1.5000 (-0.66%)
AIM : 2.09 (+1.46%)
AIRI : 1.1100 (+2.78%)
ALIM : 5.70 (+1.60%)
ALJJ : 0.8560 (+1.92%)
ALLT : 9.79 (+4.04%)
ARCT : 46.89 (+2.99%)
AREC : 1.6100 (+5.92%)
AMS : 1.8100 (-1.09%)
ANVS : 5.33 (+3.50%)
APEN : 1.4800 (+8.03%)
APM : 1.6900 (-0.59%)
AQMS : 1.0400 (+7.76%)
AQB : 5.16 (+14.67%)
ARTL : 0.8500 (-3.41%)
ARHH : 0.8702 (-2.22%)
ATOM : 10.58 (+0.86%)
ATOS : 2.44 (+5.17%)
AUTO : 3.59 (-0.28%)
AYRO : 2.79 (-7.00%)
AZRX : 0.8150 (-1.26%)
BELFA : 10.50 (-3.67%)
BCDA : 2.45 (+4.70%)
BIOC : 4.49 (+2.51%)
BHTG : 1.2500 (-1.57%)
BIOL : 0.3050 (-1.99%)
BKEP : 1.5100 (+0.67%)
ATDS : 0.0111 (+7.77%)
ASUR : 7.61 (-0.78%)
BEER.VN : 0.055 (-8.33%)
ANY : 2.56 (+4.92%)
Biocept Provides COVID-19 Testing Update with More Than 21,000 COVID-19 Specimens Received and More than 20,000 Specimens Processed

, /PRNewswire/ -- . (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve patient outcomes, announces...

BIOC : 4.49 (+2.51%)
Biocept to Present at the LD Micro 500 Virtual Conference

, /PRNewswire/ -- . (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients, announces...

BIOC : 4.49 (+2.51%)
Biocept Names Michael Dugan, M.D. Chief Medical Officer and Medical Director

Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients, announces the...

DGX : 113.87 (+1.14%)
BIOC : 4.49 (+2.51%)
Biocept to Present at the Proactive One2One Virtual Investor Forum on August 25

Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients, announces that...

BIOC : 4.49 (+2.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade BIOC with:

Business Summary

Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for breast cancer. Biocept,...

See More

Key Turning Points

2nd Resistance Point 4.67
1st Resistance Point 4.58
Last Price 4.49
1st Support Level 4.38
2nd Support Level 4.26

See More

52-Week High 13.00
Fibonacci 61.8% 8.84
Fibonacci 50% 7.56
Fibonacci 38.2% 6.27
Last Price 4.49
52-Week Low 2.11

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar